Concepedia

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Alasdair Coles, Edward Fox, Anton Vladić, Suzanne Gazda, Vesna Brinar, Krzysztof Selmaj, Ann Bass, Daniel Wynn, David Margolin, Stephen Lake,

The Lancet Neurology · 2011 · 138 citations · 8 references

DOI

Concepts

References

8

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.9K citations

, , +14

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

The CAMMS Trial Investigators · New England Journal of Medicine · 2008 · 1K citations · Full text

, , +17

The window of therapeutic opportunity in multiple sclerosis

Alasdair Coles, Amanda Cox, Emmanuelle Le Page et al. · Journal of Neurology · 2005 · 505 citations

, , +14

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Eva Havrdová, Steven Galetta, Michael Hutchinson et al. · The Lancet Neurology · 2009 · 473 citations

, , +10

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis

Amanda Cox, Sara Thompson, Joanne Jones et al. · European Journal of Immunology · 2005 · 290 citations · Full text

, , +13